GLP-1 Medications and Addiction: Can Weight-Loss Drugs Help with Alcohol Use Disorder?

Short summary

Science Friday explores GLP-1 receptor agonists, drugs originally used for weight loss and diabetes, and their off-label potential to affect alcohol and other substance use. The episode presents evidence from animal studies, EMR analyses, and early clinical trials, and discusses the biology of addiction, the need for comprehensive care, and practical issues around access and stigma.

• GLP-1s may reduce craving and consumption by altering brain reward pathways, not just by making people feel sick.
• Evidence comes from three lines of research at different stages: preclinical studies, big-data EMR studies, and randomized trials.
• Medication should be paired with behavioral health services to address trauma and coping mechanisms.
• Access and equity will be key challenges as these medications move toward potential addiction therapies.

Overview

In this Science Friday episode, Flora Lichtman hosts a discussion about GLP-1 receptor agonists, drugs approved for weight loss and diabetes, and the off-label possibility that they could affect alcohol and other substance use. The guests, Dr. Joseph Schacht and Sarah Carstens, describe the current evidence base, what remains uncertain, and how these findings might influence addiction biology and treatment approaches.

"there are sort of three lines of evidence that are in different stages." - Dr. Joseph Schacht

Evidence Landscape

The conversation outlines three streams of evidence. First, preclinical animal studies have shown that GLP-1 agonists can reduce alcohol consumption in models of addiction. Second, electronic medical record analyses across large health systems have observed fewer alcohol-related events among patients treated with GLP-1 drugs for obesity or diabetes. Third, randomized clinical trials have begun to probe efficacy for alcohol use disorder, including trials involving injectable semaglutide, with mixed but encouraging signals so far. The teams anticipate more robust trial results in the next six months, which could clarify who might benefit most from these therapies.

"There are GLP1 receptors in the parts of the brain that fundamentally contribute to craving and to wanting things and to being unable to control use of alcohol or other substances." - Dr. Joseph Schacht

Possible Mechanisms

A key question is how GLP-1 drugs could influence addiction biology. Experts differentiate gastrointestinal side effects, common with GLP-1 therapies, from real shifts in craving and drinking. The mechanisms may involve GLP-1 receptors in reward circuits such as the nucleus accumbens, brain regions that drive craving, motivation, and impulse control. There are hypotheses that these medications either cross the blood-brain barrier, or act indirectly via gut-brain signaling and natural GLP-1 pathways. The potential for caloric and metabolic effects to intersect with substance-use pathways is also discussed, given alcohol’s caloric nature.

"The nucleus accumbens, which is in the basal ganglia, the lizard part of the brain, is a key region where GLP-1 receptors could influence craving." - Dr. Joseph Schacht

Clinical and Societal Considerations

Clinicians emphasize that addiction is a brain disease. Medications like GLP-1 agonists may help, but they must be combined with behavioral health supports, trauma-informed care, and nutrition management to address the full spectrum of contributors to substance use. Stigma around using medications for addiction persists, though some experts see GLP-1s as potentially less stigmatizing than traditional addiction medications. Access and representation are major concerns, as these drugs become more widely considered for addiction indications.

"Access has to be a consideration." - Sarah Carstens

Flora notes the risk of nutritional deficits in individuals with long histories of alcohol use when appetite is suppressed by GLP-1 therapies, underscoring the need for integrated care with nutrition professionals.

"Medication alone cannot be the answer." - Flora Lichtman

Takeaways and Future Outlook

The panel discusses how results from ongoing and upcoming trials could reshape clinical practice, including identifying which patient populations might benefit most and how GLP-1–related mechanisms might unify obesity, alcohol, and other craving-driven disorders under a common neurobiological framework. The conversation closes with the reminder that science, medicine, and policy must address access, equity, and compassionate care as new therapies emerge.

"It's too early to do that. Alcohol and substance use disorders are very challenging to treat." - Flora Lichtman